Verinata Health Files Patent Infringement Action Against Ariosa Diagnostics, Inc. And Laboratory Corporation Of America

 Verinata Health Files Patent Infringement Action Against Ariosa Diagnostics,
             Inc. And Laboratory Corporation Of America Holdings

PR Newswire

REDWOOD CITY, Calif., Oct. 25, 2012

REDWOOD CITY, Calif., Oct. 25, 2012 /PRNewswire/ --Verinata Health, Inc., a
privately-held company dedicated to maternal and fetal health, today announced
that it has commenced an action against Ariosa Diagnostics, Inc. (Ariosa) and
Laboratory Corporation of America Holdings (LabCorp) in federal court in the
Northern District of California. The action asserts that Ariosa and LabCorp
infringe U. S. Patent No. 8,296,076 (the '076 patent) entitled "Noninvasive
Diagnosis of Fetal Aneuploidy by Sequencing" by offering and performing the
Harmony^TM prenatal test, among other activities. The '076 patent, which
claims priority to a U.S. application filed on September 20, 2008, issued to
Stanford University on October 23, 2012. Verinata is bringing the action
against Ariosa and LabCorp as an exclusive licensee of the patent in the field
of genetic analysis by nucleic acid sequencing. Stanford is joined in the
suit as a necessary party because it is the registered owner of the '076
patent. In the complaint, Verinata seeks an injunction to halt Ariosa's and
LabCorp's infringement of the '076 patent, in addition to damages and other
relief.

(Logo: http://photos.prnewswire.com/prnh/20120425/SF94380LOGO)

"We believe that we have the leading intellectual property in the field of
non-invasive prenatal diagnostics using sequencing of cell-free DNA, and that
the in-licensed patents from Stanford University are an important part of that
intellectual property estate," stated Dr. Jeffrey Bird, Executive Chairman and
Chief Executive Officer of Verinata. "Including the patents in-licensed from
Stanford, Verinata now owns or holds an exclusive license to 11 U. S. patents
and 16 foreign patents in the field of non-invasive prenatal diagnostics. We
believe that the Stanford '076 patent granted on the 23rd is a fundamental
patent, and that Ariosa's prenatal test falls under its claims as we have set
forth in the complaint. Verinata remains fully committed to its mission of
providing high quality non-invasive prenatal testing to all women desiring
such testing. As a part of this mission, Verinata will continue to actively
market its industry-leading verifi® prenatal test for the determination of
fetal chromosomal aneuploidies."

About the verifi® prenatal test
The verifi® prenatal test is a blood test that analyzes genetic material (or
DNA) naturally found in a pregnant woman's blood to detect Down syndrome
(trisomy 21 or T21), Edwards syndrome (trisomy 18 or T18), Patau syndrome
(trisomy 13 or T13) and Turner syndrome (monosomy X) in the fetus. When
directed by a physician, the verifi test can be offered to pregnant women of
at least 10 weeks gestation at high risk of carrying a fetus with a genetic
abnormality. A physician may classify a woman as "high-risk" if she is over 35
years of age, has a prior personal or family history of chromosome
abnormalities, or has had a positive initial screening test indicating she is
at increased risk for carrying a fetus with a genetic abnormality.

Verinata Health, Inc.
Verinata is driven by a sole, extraordinary purpose – maternal and fetal
health. Our initial focus is to develop and offer non-invasive tests for early
identification of fetal chromosomal abnormalities using our proprietary
technologies. We aim to reduce the anxiety associated with today's multi-step
process, the unacceptable false-positive rates, the non-specific and sometimes
confusing results of current prenatal screening methods, as well as the risk
of current invasive procedures. In support of national guidelines recommending
first trimester aneuploidy risk assessment, we believe women who desire such
an assessment should be offered a single blood draw test with a definitive
result. The verifi® prenatal test is available throughout the United States,
with the exception of New York, through a physician. For more information
about Verinata, please go to www.verinata.com.

SOURCE Verinata Health, Inc.

Website: http://www.verinata.com
Contact: Angela Bitting, For Verinata Health, (925) 202-6211,
abitting@verinata.com, Media Inquiries: Denise Powell, WCG , (510) 703-9491,
dpowell@wcgworld.com
 
Press spacebar to pause and continue. Press esc to stop.